Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Emerging Giants: AI-Driven Innovators Under $2 Set to Transform Markets INBS, PRSO, LPSN, PACB, NINE
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Tickers INBS PRSO
Why Choose Capsule Tablet Metal Detector in Pharmaceutical Industry?
Via AB Newswire
Topics Product Recall
Exposures Legal Product Safety
FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
Via Benzinga
Exposures Product Safety
Tickers NVS
JD.JUNE’s Bodysuits for Bosses: Revolutionizes Corporate America
Via Syndication Cloud
Topics Product Recall
Exposures Legal Product Safety
BMW Recalls Over 105K Vehicles In U.S. Over Fire Risks Due To Overheating Starter Motor
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers BMWYY
YouthBio Therapeutics Announces Significant Results from Joint Study with Dr. Ocampo Demonstrating Amelioration of Age-Related Cognitive Decline
Via PRLog
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Actuated Medical Developing Technology to Improve Targeting for Next-Generation Alcohol Use Disorder Treatments
Via PRLog
Topics Intellectual Property
Exposures COVID-19 Intellectual Property Product Safety
Mental Health Watchdog Urges FDA to Ban Electroshock Device
Via PRLog
Topics Death Lawsuit
Exposures Death Financial Legal
3 Biotech Stocks With Promising Drug Pipelines: August 2024
Via InvestorPlace
Exposures Product Safety
Tickers BMY BNTX REGN
Five Out Of Six Studies On MDMA Show Positive Results, Yet FDA Approval Still Faces Hurdles
Via Benzinga
Exposures Product Safety
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
Via Benzinga
Exposures Product Safety
Tickers EXEL
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Via Benzinga
Exposures Product Safety
Tickers NVO
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates
Via Investor Brand Network
Exposures Product Safety
Tickers CLNN
Amgen's MariTide Weight Loss Potential: Stock Outlook
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers AMGN LLY NVO XLV
Tesla Recalls 1.7M Vehicles In China Over Concerns Of Front Trunk Opening When Driving, After Recalling 1.8M Vehicles In US Over Similar Problems: To Fix Issue Via Over-The-Air Software Upgrade
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers TSLA
JRE Offers Highly Durable Crimping Machines at Reasonable Rates
Via Get News
Exposures Product Safety
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Submits New CNM-Au8 Biomarker, Clinical Efficacy Data to FDA
Via Investor Brand Network
Exposures Product Safety
Tickers CLNN
Senators Press FDA To Approve MDMA As PTSD Treatment, Stressing US Vets' Suicide Rates As Aug 11 Decision Looms
Via Benzinga
Exposures Product Safety
BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Schedules Release of Q2 2024 Financial Results, Earnings Conference Call
Via Investor Brand Network
Exposures Product Safety
Tickers LGVN
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease
Via News Direct
Exposures Product Safety
Tickers ALZN
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
Via PressReach
Exposures Product Safety
Tickers ABBV ALZN ITCI TEVA
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
Via PressReach
Exposures Product Safety
Tickers ALZN
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Via PressReach
Exposures Product Safety
Tickers ALZN
Headline
Via News Direct
Exposures Product Safety
Tickers ALZN
Delegate to Elevate Transforms Entrepreneurial Success Stories Through Strategic Outsourcing
Via Prodigy
Topics Product Recall
Exposures Legal Product Safety
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate
Via Investor Brand Network
Exposures Product Safety
Tickers PXMD
FDA Clears Incannex To Proceed With Phase 2 Psilocybin-Assisted Therapy Trial For Anxiety
Via Benzinga
Exposures Product Safety
Tickers IXHL
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
Via Benzinga
Exposures Product Safety
Tickers ATNM
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
Via Benzinga
Exposures Product Safety
Tickers ZVRA
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
Via Benzinga
Exposures Product Safety
Tickers ALZN
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.